RELMADA THERAPEUTICS, INC. 8-K

What Happened

• On March 19, 2026, Relmada Therapeutics, Inc. (RLMD) issued a press release providing a corporate update and reporting its financial results for the fiscal year ended December 31, 2025. The company announced a conference call and audio webcast that same day (Thursday, March 19, 2026) at 4:30 PM EST / 1:30 PM PST to discuss the update and results. Relmada noted that its complete audited financial statements and related notes for the years ended December 31, 2025 and 2024 will be included in its Annual Report on Form 10‑K to be filed with the SEC.

Key Details

• Filing date: March 19, 2026 (8-K Items 2.02 and 7.01).
• Reporting period: fiscal year ended December 31, 2025.
• Conference call/webcast: March 19, 2026 at 4:30 PM EST / 1:30 PM PST.
• Documents furnished: press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2).

Why It Matters

• The 8-K signals material year‑end results and a management update; investors should review the press release and the updated corporate presentation now and listen to the conference call for management commentary. The filing also indicates audited, detailed financial statements will follow in the company’s forthcoming Form 10‑K, which investors should read when posted for full, audited figures and disclosures.